KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Boston Scientific (BSX) EPS (Weighted Average and Diluted) (2016 - 2026)

Boston Scientific's EPS (Weighted Average and Diluted) history spans 18 years, with the latest figure at $0.9 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 100.0% to $0.9 in Q1 2026 year-over-year; TTM through Mar 2026 was $2.39, a 74.45% increase, with the full-year FY2025 number at $1.94, up 55.2% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.9 in Q1 2026 for Boston Scientific, up from $0.45 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for BSX hit a ceiling of $0.9 in Q1 2026 and a floor of $0.07 in Q1 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged $0.33 across 5 years, with a median of $0.33 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 69.57% in 2022 and later surged 277.78% in 2023.
  • Tracing BSX's EPS (Weighted Average and Diluted) over 5 years: stood at $0.09 in 2022, then surged by 277.78% to $0.34 in 2023, then rose by 11.76% to $0.38 in 2024, then rose by 18.42% to $0.45 in 2025, then soared by 100.0% to $0.9 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BSX at $0.9 in Q1 2026, $0.45 in Q4 2025, and $0.51 in Q3 2025.